Skip to main content
    • Aa
    • Aa
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 28
  • Cited by
    This article has been cited by the following publications. This list is generated based on data provided by CrossRef.

    Wesnes, Keith A and Edgar, Chris J 2014. The role of human cognitive neuroscience in drug discovery for the dementias. Current Opinion in Pharmacology, Vol. 14, p. 62.

    Ortner, Marion and Diehl-Schmid, Janine 2015. Alzheimer-Diagnose bei Jüngeren. DNP - Der Neurologe und Psychiater, Vol. 16, Issue. 3, p. 39.

    Warren, Jason D. Fletcher, Phillip D. and Golden, Hannah L. 2012. The paradox of syndromic diversity in Alzheimer disease. Nature Reviews Neurology,

    Stanley, Karen and Walker, Zuzana 2014. Do patients with young onset Alzheimer's disease deteriorate faster than those with late onset Alzheimer's disease? A review of the literature. International Psychogeriatrics, Vol. 26, Issue. 12, p. 1945.

    Sakai, Minoru Hanyu, Haruo Kume, Kazumasa Sato, Tomohiko Hirao, Kentaro Kanetaka, Hidekazu Abe, Shine Kanaya, Kiyoshi Sakurai, Hirofumi and Iwamoto, Toshihiko 2013. Rate of progression of Alzheimer's disease in younger versus older patients: A longitudinal single photon emission computed tomography study. Geriatrics & Gerontology International, Vol. 13, Issue. 3, p. 555.

    ten Kate, Mara Sanz-Arigita, Ernesto J. Tijms, Betty M. Wink, Alle Meije Clerigue, Montserrat Garcia-Sebastian, Maite Izagirre, Andrea Ecay-Torres, Miriam Estanga, Ainara Villanua, Jorge Vrenken, Hugo Visser, Pieter Jelle Martinez-Lage, Pablo and Barkhof, Frederik 2016. Impact of APOE-ɛ4 and family history of dementia on gray matter atrophy in cognitively healthy middle-aged adults. Neurobiology of Aging, Vol. 38, p. 14.

    Serrano-Pozo, Alberto Qian, Jing Monsell, Sarah E. Betensky, Rebecca A. and Hyman, Bradley T. 2015. APOEε2 is associated with milder clinical and pathological Alzheimer disease. Annals of Neurology, Vol. 77, Issue. 6, p. 917.

    Louwersheimer, Eva Ramirez, Alfredo Cruchaga, Carlos Becker, Tim Kornhuber, Johannes Peters, Oliver Heilmann, Stefanie Wiltfang, Jens Jessen, Frank Visser, Pieter Jelle Scheltens, Philip Pijnenburg, Yolande A.L. Teunissen, Charlotte E. Barkhof, Frederik van Swieten, John C. Holstege, Henne and Van der Flier, Wiesje M. 2015. The influence of genetic variants in SORL1 gene on the manifestation of Alzheimer's disease. Neurobiology of Aging, Vol. 36, Issue. 3, p. 1605.e13.

    Schmidt, Christian Wolff, Martin von Ahsen, Nicolas and Zerr, Inga 2012. Alzheimer’s Disease: Genetic Polymorphisms and Rate of Decline. Dementia and Geriatric Cognitive Disorders, Vol. 33, Issue. 2-3, p. 84.

    Bakker, Christian de Vugt, Marjolein E. van Vliet, Deliane Verhey, Frans R.J. Pijnenburg, Yolande A. Vernooij-Dassen, Myrra J.F.J. and Koopmans, Raymond T.C.M. 2013. Predictors of the Time to Institutionalization in Young- Versus Late-Onset Dementia: Results From the Needs in Young Onset Dementia (NeedYD) Study. Journal of the American Medical Directors Association, Vol. 14, Issue. 4, p. 248.

    Rossor, Martin N Fox, Nick C Mummery, Catherine J Schott, Jonathan M and Warren, Jason D 2010. The diagnosis of young-onset dementia. The Lancet Neurology, Vol. 9, Issue. 8, p. 793.

    Tosto, G. Gasparini, M. Brickman, A. M. Letteri, F. Renie', R. Piscopo, P. Talarico, G. Canevelli, M. Confaloni, A. and Bruno, G. 2015. Neuropsychological predictors of rapidly progressive Alzheimer's disease. Acta Neurologica Scandinavica, Vol. 132, Issue. 6, p. 417.

    Sabbagh, Marwan Cummings, Jeffrey Christensen, Daniel Doody, Rachelle Farlow, Martin Liu, Liang Mackell, Joan and Fain, Randi 2013. Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer’s disease: analysis of effects of baseline features on treatment response. BMC Geriatrics, Vol. 13, Issue. 1,

    Möller, Christiane Vrenken, Hugo Jiskoot, Lize Versteeg, Adriaan Barkhof, Frederik Scheltens, Philip and van der Flier, Wiesje M. 2013. Different patterns of gray matter atrophy in early- and late-onset Alzheimer’s disease. Neurobiology of Aging, Vol. 34, Issue. 8, p. 2014.

    Smits, Lieke L. Pijnenburg, Yolande A.L. van der Vlies, Annelies E. Koedam, Esther L.G.E. Bouwman, Femke H. Reuling, Ilona E.W. Scheltens, Philip and van der Flier, Wiesje M. 2015. Early onset APOE E4-negative Alzheimer’s disease patients show faster cognitive decline on non-memory domains. European Neuropsychopharmacology, Vol. 25, Issue. 7, p. 1010.

    De Luca, Vincenzo Orfei, Maria Donata Gaudenzi, Sara Caltagirone, Carlo and Spalletta, Gianfranco 2015. Inverse effect of the APOE epsilon4 allele in late- and early-onset Alzheimer’s disease. European Archives of Psychiatry and Clinical Neuroscience,

    Ossenkoppele, Rik Tolboom, Nelleke Foster-Dingley, Jessica C. Adriaanse, Sofie F. Boellaard, Ronald Yaqub, Maqsood Windhorst, Albert D. Barkhof, Frederik Lammertsma, Adriaan A. Scheltens, Philip van der Flier, Wiesje M. and van Berckel, Bart N. M. 2012. Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET. European Journal of Nuclear Medicine and Molecular Imaging, Vol. 39, Issue. 6, p. 990.

    한노을, 나덕렬, 서상원, 진주희, and 이병화, 2012. Neuropsychological Characteristics and Rates of Conversion to Dementia in Early-and Late-onset Mild Cognitive Impairment. The Korean Journal of Clinical Psychology, Vol. 31, Issue. 1, p. 373.

    de Waal, Hanneke Stam, Cornelis J. de Haan, Willem van Straaten, Elisabeth C.W. Blankenstein, Marinus A. Scheltens, Philip and van der Flier, Wiesje M. 2013. Alzheimer's disease patients not carrying the apolipoprotein E ε4 allele show more severe slowing of oscillatory brain activity. Neurobiology of Aging, Vol. 34, Issue. 9, p. 2158.

    van der Flier, Wiesje M Pijnenburg, Yolande AL Fox, Nick C and Scheltens, Philip 2011. Early-onset versus late-onset Alzheimer's disease: the case of the missing APOE ɛ4 allele. The Lancet Neurology, Vol. 10, Issue. 3, p. 280.


Most rapid cognitive decline in APOE ε4 negative Alzheimer's disease with early onset

  • A. E. van der Vlies (a1), E. L. G. E. Koedam (a1), Y. A. L. Pijnenburg (a1), J. W. R. Twisk (a2), P. Scheltens (a1) and W. M. van der Flier (a1)
  • DOI:
  • Published online: 01 April 2009

We aimed to compare the rate of cognitive decline in patients with early and late onset Alzheimer's disease (AD) and to investigate the potentially modifying influence of the apolipoprotein E (APOE) genotype.


We included 99 patients with early onset AD (age ⩽65 years) and 192 patients with late onset AD (age >65 years) who had at least two scores on the Mini-Mental State Examination (MMSE) (range 2–14) obtained at least 1 year apart. Linear mixed models were performed to investigate the rate of cognitive decline dependent on age at onset (AAO) and APOE genotype.


The mean (s.d.) age for patients with early onset AD was 57.7 (4.5) years, and 74.5 (5.1) years for patients with late onset AD. AAO was not associated with baseline MMSE [β (s.e.)=0.8 (0.5), p=0.14]. However, patients with early onset showed a faster decline on the MMSE [β (s.e.)=2.4 (0.1) points/year] than those with late onset [β (s.e.)=1.7 (0.1) points/year, p=0.00]. After stratification according to APOE genotype, APOE ε4 non-carriers with early onset showed faster cognitive decline than non-carriers with late onset [2.4 (0.3) v. 1.3 (0.3) points/year, p=0.01]. In APOE ε4 carriers, no difference in rate of cognitive decline was found between patients with early and late onset [β (s.e.)=0.2 (0.2), p=0.47].


Patients with early onset AD show more rapid cognitive decline than patients with late onset, suggesting that early onset AD follows a more aggressive course. Furthermore, this effect seems to be most prominent in patients with early onset who do not carry the genetic APOE ε4 risk factor for AD.

Corresponding author
*Address for correspondence: A. E. van der Vlies, Department of Neurology and Alzheimer Centre, VU University Medical Centre, PO Box 7057, 1007 MBAmsterdam, The Netherlands. (Email:
Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

K Blennow , MJ de Leon , H Zetterberg (2006). Alzheimer's disease. Lancet 368, 387403.

Y Davidson , L Gibbons , A Pritchard , J Hardicre , J Wren , C Stopford , C Julien , J Thompson , A Payton , SM Pickering-Brown , N Pendleton , MA Horan , A Burns , N Purandare , CL Lendon , D Neary , JS Snowden , DM Mann (2007). Apolipoprotein E epsilon4 allele frequency and age at onset of Alzheimer's disease. Dementia and Geriatric Cognitive Disorders 23, 6066.

MF Folstein , SE Folstein , PR McHugh (1975). ‘Mini-mental state’. A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research 12, 189198.

GB Frisoni , S Govoni , C Geroldi , A Bianchetti , L Calabresi , G Franceschini , M Trabucchi (1995). Gene dose of the epsilon-4 allele of apolipoprotein-E and disease progression in sporadic late onset Alzheimer's disease. Annals of Neurology 37, 596604.

MD Greicius , MD Geschwind , BL Miller (2002). Presenile dementia syndromes: an update on taxonomy and diagnosis. Journal of Neurology, Neurosurgery and Psychiatry 72, 691700.

FJ Huff , JH Growdon , S Corkin , TJ Rosen (1987). Age at onset and rate of progression of Alzheimer's disease. Journal of the American Geriatrics Society 35, 2730.

D Jacobs , M Sano , K Marder , K Bell , F Bylsma , G Lafleche , M Albert , J Brandt , Y Stern (1994). Age at onset of Alzheimer's disease: relation to pattern of cognitive dysfunction and rate of decline. Neurology 44, 12151220.

T Kleiman , K Zdanys , B Black , T Rightmer , M Grey , K Garman , M MacAvoy , J Gelernter , C van Dyck (2006). Apolipoprotein E e4 allele is unrelated to cognitive or functional decline in Alzheimer's disease: retrospective and prospective analysis. Dementia and Geriatric Cognitive Disorders 22, 7382.

J Kuusisto , K Koivisto , K Kervinen , L Mykkanen , EL Helkala , M Vanhanen , T Hanninen , K Pyorala , YA Kesaniemi , P Riekkinen , M Laakso (1994). Association of apolipoprotein-E phenotypes with late onset Alzheimer's disease: population-based study. British Medical Journal 309, 636638.

DM Mann , PO Yates , B Marcyniuk (1984). Alzheimer's presenile dementia, senile dementia of Alzheimer type and Down's syndrome in middle age form an age-related continuum of pathological changes. Neuropathology and Applied Neurobiology 10, 185207.

CAR Martins , A Oulhaj , CA de Jager , JH Williams (2005). APOE alleles predict the rate of cognitive decline in Alzheimer disease: a nonlinear model. Neurology 65, 18881893.

G McKhann , D Drachman , M Folstein , R Katzman , D Price , EM Stadlan (1984). Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939944.

RC Petersen , RG Thomas , M Grundman , D Bennett , R Doody , S Ferris , D Galasko , S Jin , J Kaye , A Levey , E Pfeiffer , M Sano , CH van Dyck , LJ Thal (2005). Vitamin E and donepezil for the treatment of mild cognitive impairment. New England Journal of Medicine 352, 23792388.

J Poirier , J Davignon , D Bouthillier , S Kogan , P Bertrand , S Gauthier (1993). Apolipoprotein E polymorphism and Alzheimer's disease. Lancet 342, 697699.

A Ruitenberg , S Kalmijn , MAJ de Ridder , WK Redekop , F van Harskamp , A Hofman , LJ Launer , MMB Breteler (2001). Prognosis of Alzheimer's disease: the Rotterdam Study. Neuroepidemiology 20, 188195.

B Seltzer , I Sherwin (1983). A comparison of clinical features in early- and late-onset primary degenerative dementia: one entity or two? Archives of Neurology 40, 143146.

AJ Slooter , JJ Houwing-Duistermaat , F van Harskamp , M Cruts , C Van Broeckhoven , MM Breteler , A Hofman , T Stijnen , CM van Duijn (1999). Apolipoprotein E genotype and progression of Alzheimer's disease: the Rotterdam Study. Journal of Neurology 246, 304308.

AJC Slooter , M Cruts , S Kalmijn , A Hofman , MMB Breteler , C Van Broeckhoven , CM van Duijn (1998). Risk estimates of dementia by apolipoprotein E genotypes from a population-based incidence study: the Rotterdam Study. Archives of Neurology 55, 964968.

JD Sluimer , H Vrenken , MA Blankenstein , NC Fox , P Scheltens , F Barkhof , WM van der Flier (2008). Whole-brain atrophy rate in Alzheimer's disease: identifying FAST progressors. Neurology 70, 18361841.

Y Stern , J Brandt , M Albert , DM Jacobs , XH Liu , K Bell , K Marder , M Sano , S Albert , CD Castenada , F Bylsma , B Tycko , R Mayeux (1997). The absence of an apolipoprotein epsilon 4 allele is associated with a more aggressive form of Alzheimer's disease. Annals of Neurology 41, 615620.

WJ Strittmatter , AD Roses (1995). Apolipoprotein E and Alzheimer's disease. Proceedings of the National Academy of Sciences USA 92, 47254727.

WJ Strittmatter , AM Saunders , D Schmechel , M Pericak-Vance , J Enghild , GS Salvesen , AD Roses (1993). Apolipoprotein E: high-avidity binding to β-amyloid and increased frequency of type 4 allele in late onset familial Alzheimer disease. Proceedings of the National Academy of Sciences USA 90, 19771981.

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Psychological Medicine
  • ISSN: 0033-2917
  • EISSN: 1469-8978
  • URL: /core/journals/psychological-medicine
Please enter your name
Please enter a valid email address
Who would you like to send this to? *